Global Leading Market Research Publisher QYResearch announces the release of its latest report “Ciclesonide Inhalation Aerosol – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Ciclesonide Inhalation Aerosol market, including market size, share, demand, industry development status, and forecasts for the next few years.
Addressing core industry needs: Asthma patients require inhaled corticosteroids (ICS) for airway inflammation control – but some ICS agents have systemic side effects or require activation. Ciclesonide inhalation aerosol solves this as a prodrug activated locally in the lungs, offering targeted anti-inflammatory action with minimal systemic exposure. Key drivers include asthma prevalence, preference for once-daily dosing, and favorable safety profile.
The global market for Ciclesonide Inhalation Aerosol was estimated to be worth US$ 171 million in 2025 and is projected to reach US$ 219 million, growing at a CAGR of 3.7% from 2026 to 2032. In 2024, the average global price was approximately US$ 24.6 per unit, with total sales reaching around 6.71 million units.
Ciclesonide Inhalation Aerosol is a prescription medication used for the control and prevention of asthma in adults and children aged 12 years and older. The aerosol delivers fine particles of the active ingredient deep into the airways, effectively reducing airway inflammation. Upstream raw materials include the active pharmaceutical ingredient (API), propellants, and high-purity aluminum aerosol cans. APIs are typically supplied by GMP-certified pharmaceutical ingredient manufacturers, while aluminum cans and excipients are provided by leading global material suppliers to ensure safety, stability, and compliance. Key manufacturers include Covis Pharma, Zentiva, AstraZeneca, Zhejiang Xianjun Pharmaceutical, and Anhui Wellman Pharmaceutical. These companies possess comprehensive pharmaceutical R&D and production capabilities, adhering strictly to Good Manufacturing Practice (GMP) and regulatory standards across multiple regions. Downstream customers consist primarily of hospitals, pharmacies, and healthcare institutions, ultimately serving patients worldwide who require safe, stable, and effective asthma inhalation therapy.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098295/ciclesonide-inhalation-aerosol
Market Segmentation & Key Players
The Ciclesonide Inhalation Aerosol market is segmented as below:
Leading Suppliers: Covis Pharma, Zentiva, AstraZeneca, Zhejiang Xianjun Pharmaceutical, Anhui Wellman Pharmaceutical.
Segment by Type: 80mcg | 100mcg
Segment by Application: Asthma | COPD | Others
Exclusive Industry Insights
Discrete pressurized MDI manufacturing: Ciclesonide MDIs are manufactured via pressure-fill process – micronized ciclesonide API (particle size <5μm) suspended in HFA propellant, filled into aluminum canisters with metering valves. Prodrug activation: ciclesonide converts to active des-ciclesonide via esterases in lung tissue.
Technical differentiation – dosage strengths:
- 80mcg (45% revenue): For mild-to-moderate asthma, pediatric use (12+ years), step-down therapy.
- 100mcg (55% revenue): For moderate-to-severe asthma, patients requiring higher ICS dose. Fastest-growing (CAGR 4.2%).
Recent 6-month data (Oct 2025 – Mar 2026):
- Asthma dominates (88% of revenue), with COPD off-label use growing.
- Generic ciclesonide MDIs entered European market in 2025 (Zentiva), capturing 18% share.
- Once-daily dosing advantage over twice-daily ICS (e.g., beclomethasone, budesonide).
User case – Regional health system (US, 200,000 asthma patients): Formulary addition of generic ciclesonide MDI (100mcg) as preferred once-daily ICS reduced annual drug cost by 22% compared to branded fluticasone (twice-daily). Patient adherence improved from 58% to 71% (once-daily convenience).
Clinical advantages of ciclesonide:
| Feature | Ciclesonide | Traditional ICS (Fluticasone, Budesonide) |
|---|---|---|
| Dosing frequency | Once daily | Twice daily |
| Activation | Prodrug (lung-activated) | Directly active |
| Systemic exposure | Low (99% protein bound, first-pass) | Moderate |
| Oral deposition | Minimal (reduces candidiasis) | Higher |
Application insights: Asthma (88%) – maintenance therapy for persistent asthma, step 2–4 per GINA guidelines. COPD (8%) – off-label for eosinophilic phenotype. Others (4%) – allergic rhinitis (nasal spray formulation).
Regional snapshot: North America leads with 58% revenue share (branded Alvesco® market). Europe holds 28% (generic entry in 2025). Asia-Pacific fastest-growing (CAGR 5.2%), driven by asthma diagnosis rates.
Conclusion
The ciclesonide inhalation aerosol market grows modestly, driven by once-daily dosing advantage, favorable safety profile, and generic entry. Success depends on propellant transition planning, generic competition management, and GMP compliance. The projected US$ 219 million market by 2032 appears achievable.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
